Roche presents positive topline CGM accuracy data at the 17th International Conference on Advanced Technologies and Treatments for Diabetes

• At the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy, Roche shared recent accuracy data for its new Accu-Chek SmartGuide solution for real-time continuous glucose monitoring (rtCGM).
• International experts discussed how a novel CGM solution using prediction capabilities can address unmet needs of people with diabetes at the Roche symposium.
• The presented study results underlined the accurate and safe performance of the solution.

Roche (SIX: RO, ROG; OTCQX: RHHBY) presented the latest data on its novel solution for continuous glucose monitoring. The solution consists of a CGM sensor and two apps designed to display current glucose values and predictions over 30 minutes and two hours. In addition, it features a risk prediction for nocturnal hypoglycemia. Roche is currently working on obtaining CE mark for the Accu-Chek SmartGuide device and will start to launch the solution in selected European countries soon after the clearance.

During the company’s symposium on the occasion of the 17th ATTD International Conference in Florence, Italy, chaired by Professor Chantal Mathieu, University of Leuven, Belgium and Professor Francesco Giorgino, University of Bari, Italy, recent accuracy and performance data of the new CGM solution were shared. Despite the advancements made in diabetes therapy and the increased uptake of technology over recent years, still only 55-60% of people with diabetes reach their therapy goals.^1,2 This underlines the many unmet needs and challenges people with diabetes have in the daily management of their condition. “Fear of hypoglycaemia or hypoglycaemia unawareness, sleep disruption, intrusion in daily life and distress caused by device alarms and alerts are just some examples of the many daily challenges a person with diabetes faces”, highlighted Professor Pratik Choudhary, University of Leicester, United Kingdom. 

The Accu-Chek SmartGuide CGM solution aims to address these unmet needs. Study evidence and participants’ feedback presented by Professor Julia Mader, University of Graz, Austria, underscore the sound performance, accuracy and safety of the sensor. The study included 48 people with type 1 or type 2 diabetes wearing three sensors for a period of 14 days each. The study results showed a high system accuracy with an overall mean absolute relative deviation (MARD) of 9.2% and 99.8% of the measured glucose values in zones A and B on the Parkes Error Grid.³ “The Accu-Chek SmartGuide solution is not only highly accurate and robust in its performance in a clinical setting, but also during routine day evaluation”, illustrated Professor Mader, ”In addition, 83% of our study participants liked or very much liked the Accu-Chek SmartGuide CGM device and about 80% liked or very much liked the app design.” 

In the symposium, the Accu-Chek SmartGuide CGM solution was demonstrated to provide users with predictive insights ahead of time. Beyond the retrospective and current view on glucose values and trend estimations, it will indicate the risk of hypoglycemia in the next 30 minutes and continuously forecast how glucose will develop in the next two hours. In addition, it will estimate the risk of nocturnal hypoglycemia. “This empowers users to be in control and take preventive decisions to adjust their therapy and pre-empt complications”, stated Professor Lutz Heinemann, Duesseldorf, Germany. “Using the potential of predictive algorithms contributes to less troubleshooting and unforeseen glucose excursions, less fear of hypoglycemia and less diabetes burden.” The evaluation of the Accu-Chek SmartGuide Predict app showed that all advanced predictive features exceeded the high performance requirements.³

“We are very excited to present these positive study results of our innovative and differentiating Accu-Chek SmartGuide CGM device for the first time”, says Dr. Marcel Gmuender, Global Head of Roche Diabetes Care. “Providing users with predictive capabilities will empower them to proactively adapt their therapy so they can maintain optimal glycemic control and prevent dangerous short and long term complications.” He concluded, ”We know from recent research that glucose predictions provide people with diabetes with invaluable insights to navigate the complexities of the disease. This is one element that can help to lower the burden of daily diabetes management.”⁴

_{Sources:
¹ Fang, M. J Gen Intern Med 35, 1427–1434 (2020) | ² Sims, EK et al., Nat Med. 2021 Jul;27(7):1154-1164. | ³ Roche Data on file; data presented at Roche-sponsored symposium at the 17th ATTD International Conference, March 6, 2024, Florence, Italy (symposium recording to be available here) | ⁴ Ehrmann, D. et al, European association for the study of diabetes, 2023, Short-oral: “Anticipated reduction in hypoglycaemia fear and diabetes distress from increasing the glucose prediction of current CGM algorithms”, publication submitted JDST.}

_{From left to right - Chantal Mathieu, Julien Boisdron, Pratik Choudhary, Julia Mader, Lutz Heinemann and Francesco Giorgino.}

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 4,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines. Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief. Since 2017, mySugr, one of the most popular diabetes management apps, has been part of Roche Diabetes Care. 

For more information, please visit www.roche.com/solutions/focus-areas/diabetes
www.accu-chek.com and www.mysugr.com

All trademarks used or mentioned in this release are protected by law.